Domain Therapeutics Welcomes New Chief Medical Officer Jean-Marie Cuillerot to Advance GPCR Pipeline Domain Therapeutics appoints Jean-Marie Cuillerot, M.D., as CMO to enhance its GPCR-targeting pipeline, marking a significant milestone.

Domain Therapeutics Welcomes New Chief Medical Officer Jean-Marie Cuillerot to Advance GPCR Pipeline #France #Strasbourg #Domain_Therapeutics #GPCR #Jean-Marie_Cuillerot

Domain Therapeutics Administers First Doses in Innovative Phase I/II Cancer Trial with DT-7012 Domain Therapeutics has commenced dosing patients in a groundbreaking clinical trial of DT-7012, targeting CCR8 to address solid tumors. This therapy aims to enhance anti-tumor immunity effectively.

Domain Therapeutics Administers First Doses in Innovative Phase I/II Cancer Trial with DT-7012 #France #Strasbourg #Domain_Therapeutics #DT-7012 #CCR8

Domain Therapeutics Unveils Groundbreaking Oncology Data at AACR 2025 Conference At AACR 2025, Domain Therapeutics shared promising new data on its innovative therapies targeting oncology, showcasing potential solutions for cancer treatment.

Domain Therapeutics Unveils Groundbreaking Oncology Data at AACR 2025 Conference #USA #Chicago #oncology #Domain_Therapeutics #AACR_2025

Domain Therapeutics Introduces DT-9046, a Pioneering Oral Treatment for Inflammatory Diseases Discover the innovative capabilities of DT-9046, the first oral drug targeting PAR2, which holds transformative potential for various inflammatory diseases.

Domain Therapeutics Introduces DT-9046, a Pioneering Oral Treatment for Inflammatory Diseases #France #Strasbourg #Domain_Therapeutics #DT-9046 #PAR2